ArticleIndian journal of surgical oncology2025
Familial Papillary Thyroid Carcinoma-4 Members from a Single Family.
Article in Indian journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial non-medullary thyroid carcinoma (FNMTC) constitutes a minority of papillary thyroid carcinoma. An aggressive surgical strategy has been proposed in view of multifocality, invasiveness, nodal metastasis and higher recurrence rate. We present 4 affected family members, demonstrating aggressiveness and genetic anticipation. This study was conducted in a retrospective cohort of a family with 4 members affected with papillary thyroid carcinoma, diagnosed and treated between 2004 and 2023. The outcomes analysed were-age and stage at presentation, types of operation, histopathology, locoregional recurrence and follow-up. All the patients were female, with a mean age of 29.75 years (range 18-41 years). BRAF V600 E mutation was positive in 2/4 (50%). Besides thyroidectomy, central compartment lymph nodal dissection was done in 2/4 patients, while one patient also underwent selective lymph nodal dissection. Aggressive variant-diffuse sclerosing with hobnail features-was observed in 1/4 (25%). Lymphocytic thyroiditis was seen in 3/4 (75%). Residual thyroid required iodine ablation in 3/4 (75%). Nodal recurrence was seen in 2/4 (50%), requiring reoperation, with a mean time-to-recurrence of 7.5 years. We observed more aggressive behaviour, high risk variants, BRAF V 600E positivity, higher nodal recurrence and genetic anticipation in these 4 kindred.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.